|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
With a lower threshold for preliminary significance to p < 10(-5), we identified 11 additional SNPs in FGFR2, a well-established breast cancer-associated gene.
|
25956309 |
2015 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
When we expanded to regions, the 3p24.1 region showed an association with breast cancer risk (permutation based P = 0.027) and three regions (10p15.1, 10q26.13/FGFR2, and 16q12.2/TOX3) showed a trend toward association.
|
21795501 |
2011 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.
|
23658459 |
2013 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We thus propose a molecular mechanism by which FGFR2 can confer increased breast cancer risk that is consistent with oestrogen exposure as a major driver of breast cancer risk.
|
27236187 |
2016 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We stably overexpressed the FN target, MAGE A3, which has also been identified as a target of the breast cancer risk factor fibroblast growth factor receptor 2, and examined the functional effects in vitro and in vivo in a flank model and an orthotopic model of thyroid cancer.
|
18829569 |
2008 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published.
|
23544012 |
2013 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We obtained a significant allele P value of association with AJ breast cancer in the FGFR2 region (P = 1.5 x 10(-5), odds ratio (OR) 1.26, 95% confidence interval (CI) 1.13-1.40 at rs1078806 for all phases combined).
|
18326623 |
2008 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We observed few significant associations with breast cancer risk overall or by menopausal status other than for FGFR2 rs2981582.
|
23912956 |
2013 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We interrogated eight SNPs in intron 2 of the FGFR2 gene for 1,676 women who developed breast cancer during trial follow-up (1993-2005).
|
20056625 |
2010 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We illustrate the gain in statistical power achieved by these methods by analyzing data of 6,209 unrelated African Americans from the CARe project genotyped on the Affymetrix 6.0 chip, in conjunction with both simulated and real phenotypes, as well as by analyzing the FGFR2 locus using breast cancer GWAS data from 5,761 African-American women.
|
21541012 |
2011 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
We identified four SNPs in intron 2 of FGFR2 (which encodes a receptor tyrosine kinase and is amplified or overexpressed in some breast cancers) that were highly associated with breast cancer and confirmed this association in 1,776 affected individuals and 2,072 controls from three additional studies.
|
17529973 |
2007 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
We identified four SNPs in intron 2 of FGFR2 (which encodes a receptor tyrosine kinase and is amplified or overexpressed in some breast cancers) that were highly associated with breast cancer and confirmed this association in 1,776 affected individuals and 2,072 controls from three additional studies.
|
17529973 |
2007 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We identified four SNPs in intron 2 of FGFR2 (which encodes a receptor tyrosine kinase and is amplified or overexpressed in some breast cancers) that were highly associated with breast cancer and confirmed this association in 1,776 affected individuals and 2,072 controls from three additional studies.
|
17529973 |
2007 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have revealed significant association of FGFR2 and MAP3K1 polymorphisms with breast cancer.
|
29372690 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors.
|
31699826 |
2020 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We genotyped 13 single nucleotide polymorphisms (SNPs) densely covering a 27 kb region within intron 2 of FGFR2 including two SNPs (rs2981582 and rs1219648) significantly associated with breast cancer and a total 40 tagSNPs across 150 kb of the FGFR2 gene.
|
18285324 |
2008 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found that NEF possessed the anti-growth and anti-metastasis effect on MDA-MB-231 cells through regulating miR-374a/FGFR-2, which might provide new insight for breast cancer management.
|
31207222 |
2019 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found that FGFR2 polymorphisms interact with family history of breast cancer (interaction p = 0.003) and reproductive risk factors, namely, age at menarche (interaction p = 0.019) and parity (interaction p = 0.026).
|
19582883 |
2009 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We found FGFR2 IIIb C2 expression in breast carcinoma cell lines and, additionally, expression of the mesenchymal-specific FGFR2 IIIc splice variant in invasive breast carcinomas.
|
18337450 |
2008 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the associations of four genetic variants in the FGFR2 gene highly related to breast cancer risk and the three common tag-SNPs in the FGFR4 gene with skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study (NHS) among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 870 controls.
|
19500394 |
2009 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We confirmed associations between rs13387042 (2q35), rs4973768 (SLC4A7), rs10941679 (5p12), rs2981582 (FGFR2), rs3817198 (LSP1), rs3803662 (TOX3), and rs6504950 (STXBP4) with breast cancer.
|
23893088 |
2013 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conducted a literature review to identify case-control studies of variants in 4 genes known to affect breast cancer risk: CHEK2*1100delC; multiple variants in BRCA1 and BRCA2; and FGFR2 rs2981582.
|
20299982 |
2010 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We conclude that tissue levels of FGFR2 mRNA are unaltered in breast cancer extracts and that the splicing mechanism for this exon selection appears not to be significantly disrupted.
|
8814701 |
1996 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We assessed the hypothesis that the association between rs1219648 (FGFR2) SNP and breast cancer risk is modified by postmenopausal HT use in a population-based case-control study.
|
23435034 |
2013 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We apply the tests to a breast cancer genetic study to assess the overall effect of the FGFR2 gene on breast cancer risk.
|
22734045 |
2012 |